New approaches to the treatment of frontotemporal lobar degeneration.
about
Molecular Pathways Bridging Frontotemporal Lobar Degeneration and Psychiatric DisordersMechanisms of granulin deficiency: lessons from cellular and animal modelsTherapeutic and diagnostic challenges for frontotemporal dementiaProgranulin, a glycoprotein deficient in frontotemporal dementia, is a novel substrate of several protein disulfide isomerase family proteinsTemporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors.Progranulin modulates zebrafish motoneuron development in vivo and rescues truncation defects associated with knockdown of Survival motor neuron 1.MicroRNA-29b regulates the expression level of human progranulin, a secreted glycoprotein implicated in frontotemporal dementia.Microglial NFκB-TNFα hyperactivation induces obsessive-compulsive behavior in mouse models of progranulin-deficient frontotemporal dementia.Recent insights into the molecular genetics of dementiaBrain atrophy in primary progressive aphasia involves the cholinergic basal forebrain and Ayala's nucleus.Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U.Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management.Advanced practice nursing: meeting the caregiving challenges for families of persons with frontotemporal dementiaAbhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia.The molecular basis of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrumDissociation of frontotemporal dementia-related deficits and neuroinflammation in progranulin haploinsufficient mice.Genetic screen identifies serpin5 as a regulator of the toll pathway and CHMP2B toxicity associated with frontotemporal dementia.Genetic correction of tauopathy phenotypes in neurons derived from human induced pluripotent stem cellsReview: disruption of the postsynaptic density in Alzheimer's disease and other neurodegenerative dementias.Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology.Pharmacological treatments for frontotemporal dementias: a systematic review of randomized controlled trials.Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options.May I Cut in? Gene Editing Approaches in Human Induced Pluripotent Stem Cells.Inhibition of autophagy induction delays neuronal cell loss caused by dysfunctional ESCRT-III in frontotemporal dementia.Frontotemporal dementia and amyotrophic lateral sclerosis-associated disease protein TDP-43 promotes dendritic branchingHow much do physicians in Latin America know about behavioral variant frontotemporal dementia?
P2860
Q26766487-B8487B24-E5AF-48A3-A16F-42C198988309Q26824221-3760E772-B682-4231-87A3-83315B40DFEBQ26998919-0DC253C1-B888-41F2-A327-AF24045F953BQ28477534-E68CDEC6-86B1-4857-AE87-1F7A6324AD09Q30428012-B5B4485A-FB71-4C64-9D2F-7AF6DC026C16Q30497278-B3817F0B-23D9-45C1-ADE5-1214E351E237Q30982718-94C85017-4F0E-4DD9-B269-66404B6FC79EQ33719360-3C558210-345D-4DDF-9CAC-AE94ECC65C3BQ33830518-C6E28084-22FD-44C3-9E04-2EC1A85BD5E8Q33862883-A08B7750-722A-4D57-9F5E-A38ABB1CA008Q34044401-C06F55A9-6DAB-4F2C-B175-467747B6FA5FQ34046590-A85EF3DD-C5F7-4358-AE7C-48C33F293D38Q34145318-6A4D8292-4C9E-4E9C-AAEB-8448DBBF45DAQ35107027-8AB16ED4-AE05-41F2-9557-7F0B625CFE54Q36485513-386A2394-6D7E-4135-8993-77B6E81E891FQ37087755-5AA8DCC2-8B59-495C-8426-B5035A1CE0DFQ37274435-B4385B70-88A4-420B-9421-7770C3E05913Q37360904-6F4FD164-C767-4C5E-B69D-4A66567BE3E5Q37790804-BCB31392-3F96-4FB3-9AB0-7027AF97C0BDQ37810697-11315C97-517C-443E-BE27-D22ABA3176E1Q38155959-F8037DEC-CAFC-443A-B964-89A23B78A869Q38391397-5A47EBF7-A585-46D6-A1B3-BB509B3C4D15Q39126523-35AC3E0D-8F4A-4EB2-8C8F-A02BDE401208Q41909984-46F75480-D81E-4D26-896C-7B5B65A493AEQ42096828-6A814745-98B2-4EC6-8D64-8A095E791D93Q54187707-87E01DE6-0671-4C1C-8885-E42404426728
P2860
New approaches to the treatment of frontotemporal lobar degeneration.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
New approaches to the treatment of frontotemporal lobar degeneration.
@en
New approaches to the treatment of frontotemporal lobar degeneration.
@nl
type
label
New approaches to the treatment of frontotemporal lobar degeneration.
@en
New approaches to the treatment of frontotemporal lobar degeneration.
@nl
prefLabel
New approaches to the treatment of frontotemporal lobar degeneration.
@en
New approaches to the treatment of frontotemporal lobar degeneration.
@nl
P2860
P1476
New approaches to the treatment of frontotemporal lobar degeneration.
@en
P2093
Bruce L Miller
Keith A Vossel
P2860
P304
P356
10.1097/WCO.0B013E328318444D
P577
2008-12-01T00:00:00Z